Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

906996.pdf (3.48 MB)

Document type

Article

Version

Published version

Publication date

2025-09-15

Publication license

cc-by (c) Oken, A. C. et al., 2025
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/224705

A polycyclic scaffold identified by structure-based drug design effectively inhibits the human P2X7 receptor

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1038/s41467-025-62643-8

Abstract

TheP2X7receptorisanATP-gated ion channel that activates inflammatory pathways involved in diseases such as cancer, atherosclerosis, and neurodegeneration. However, despite the potential benefits of blocking overactive signaling, no P2X7 receptor antagonists have been approved for clinical use. Understanding species-specific pharmacological effects of existing antagonists has been challenging, in part due to the dearth of molecular information on receptor orthologs. Here, to identify distinct molecular features in the human receptor, we determine high-resolution cryo-EM structures of the fulllength wild-type human P2X7 receptor in apo closed and ATP-bound open state conformationsanddrawcomparisonswithstructuresofotherorthologs. Wealso report a cryo-EM structure of the human receptor in complex with an adamantane-based inhibitor, which we leverage, in conjunction with functional data and molecular dynamics simulations, to design a potent and selective antagonist with a unique polycyclic scaffold. Functional and structural analysis reveal how this optimized ligand, termed UB-MBX-46, interacts with the classical allosteric pocket of the human P2X7 receptor with subnanomolar potency and high selectivity, revealing its significant therapeutic potential.

Subject

Receptors cel·lulars, Inflamació, Medicaments

Subject (English)

Cell receptors, Inflammation, Drugs

Citation

Collections

Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

Citation

KIM, Yong-Chul, et al. A polycyclic scaffold identified by structure-based drug design effectively inhibits the human P2X7 receptor. Nature Communications. 2025. Vol. 16, num. 8283. ISSN 2041-1723. [consulted: 8 of August of 2026]. Available at: https://hdl.handle.net/2445/224705

Export metadata

JSON - METS

Share record